60270EF7936153E78725823500832932 Hearing Summary CLICS/CLICS2018A/commsumm.nsf PUBLICBILL SUMMARY For SB18-023SENATE COMMITTEE ON HEALTH & HUMAN SERVICESDate Feb 15, 2018 Location SCR 357 SB18-023 - Postponed Indefinitely 04:52:59 PM Senator Martinez Humenik, bill sponsor, presented Senate Bill 18-023. Under federal law, the Food and Drug Administration (FDA) is responsible for approving pharmaceutical products that may be sold in the United States, and the FDA approval process focuses on a specific use of the drug in treating a specific condition or conditions. This bill defines "off-label use" as the use of an FDA-approved prescription drug, biological product, or device in a manner other than the use approved by the FDA. Under the bill, pharmaceutical manufacturers and their representatives are allowed to truthfully promote off-label uses of pharmaceutical products. The State Board of Pharmacy is prohibited from taking disciplinary action against a manufacturer for promoting off-label uses, including revoking or failing to renew a manufacturer's license. The bill specifies that health insurance carriers and other third-party payers are not required to provide coverage for the cost of off-label uses of a prescription drug, biological product, or device. 04:58:30 PM Diane Robinson, representing herself, testified in support of the bill. 05:01:22 PM Senator Martinez Humenik made closing comments. She requested that the bill be postponed indefinitely. 05:02:37 PM Motion Postpone Senate Bill 18-023 indefinitely. Moved Crowder Seconded Aguilar Yes Crowder Yes Kefalas Yes Martinez Humenik Yes Smallwood No Final YES: 4 NO: 1 EXC: 0 ABS: 0 FINAL ACTION: PASS